Tumor News and Research

RSS

Scientists isolate enzyme that could be used to predict survival for nasopharyngeal cancer

Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Clioquinol shows promise in fighting cancer

Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

18 Apr 2007

Vitamin D: sunshine, diet and supplements - cancer prevention and therapy

Vitamin D deficiency is common and cancer risk is higher among those individuals with low vitamin D levels, according to an analysis of research which will be presented at a symposium by Donald L.

17 Apr 2007

Brain tumor vaccine shows promise

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

17 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

Johns Hopkins develops pancreas cancer risk software tool

People with a family history of pancreas cancer now have a way to accurately predict their chance of carrying a gene for hereditary pancreas cancer and their lifetime risk of developing the disease.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Access to dermatologist improves melanoma-related health outcomes

Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a non-dermatologist, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Cortical mapping helps brain tumor removal

In 2006, it was estimated that 18,820 new cases were diagnosed and 12,820 deaths were associated with malignant tumors of the brain and other parts of the central nervous system.

17 Apr 2007

Chromosomes tell tale of patient's risk for new, future cancer

Hodgkin's disease survivors who have greater genetic instability in their white blood cells are two-and-a-half times more likely to develop another type of cancer, researchers from The University of Texas M. D.Anderson Cancer Center report at the American Association for Cancer Research annual meeting in Los Angeles April 14-18.

17 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007